Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.

Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S.

Clin Gastroenterol Hepatol. 2012 Aug;10(8):941-6; quiz e68. doi: 10.1016/j.cgh.2012.04.008. Epub 2012 Apr 13.

PMID:
22507876
2.

Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.

Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O.

Clin Gastroenterol Hepatol. 2013 Jan;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003. Epub 2012 Oct 9.

PMID:
23063679
3.

Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients.

Kim YJ, Cho HC, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH.

J Gastroenterol Hepatol. 2012 Feb;27(2):306-12. doi: 10.1111/j.1440-1746.2011.06852.x.

PMID:
21777281
4.

First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.

Ozaras R, Mete B, Ceylan B, Ozgunes N, Gunduz A, Karaosmanoglu H, Cagatay A, Gokturk K, Erdem L, Kocak F, Senates E, Tabak F.

Eur J Gastroenterol Hepatol. 2014 Jul;26(7):774-80. doi: 10.1097/MEG.0000000000000099.

PMID:
24901822
5.

Resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B.

Hartono JL, Aung MO, Dan YY, Gowans M, Lim K, Lee YM, Lee GH, Low HC, Tan PS, Thwin MA, Soon C, Chiu LL, Khoo MJ, Koay E, Lim SG.

Aliment Pharmacol Ther. 2013 Apr;37(7):710-9. doi: 10.1111/apt.12251. Epub 2013 Feb 21.

6.

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.

Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P.

J Hepatol. 2012 Mar;56(3):520-6. doi: 10.1016/j.jhep.2011.09.018. Epub 2011 Oct 26.

PMID:
22037226
7.

Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.

Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, Schmutz G, Herrmann E.

J Hepatol. 2011 Dec;55(6):1235-40. doi: 10.1016/j.jhep.2011.03.030. Epub 2011 May 19.

PMID:
21703180
8.

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience.

Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH.

Clin Microbiol Infect. 2016 Jan;22(1):95.e1-95.e7. doi: 10.1016/j.cmi.2015.05.035. Epub 2015 Jun 5.

9.

Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand.

Thu AM, Poovorawan K, Kittitrakul C, Nontprasert A, Sriboonvorakul N, Phumratanaprapin W, Tangkijvanich P, Leowattana W, Wilairatana P.

BMC Pharmacol Toxicol. 2015 Dec 14;16:38. doi: 10.1186/s40360-015-0037-6.

10.

Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients.

Kamar N, Huart A, Tack I, Alric L, Izopet J, Rostaing L.

Clin Nephrol. 2009 Jan;71(1):36-42.

PMID:
19203548
11.

Renal Function in Chronic Hepatitis B Patients Treated With Tenofovir Disoproxil Fumarate or Entecavir Monotherapy: A Matched Case-Cohort Study.

Ha NB, Ku K, Ha NB, Chaung KT, Trinh HN, Nguyen MH.

J Clin Gastroenterol. 2015 Nov-Dec;49(10):873-7. doi: 10.1097/MCG.0000000000000325.

PMID:
25856383
12.

Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal.

Viganò M, Brocchieri A, Spinetti A, Zaltron S, Mangia G, Facchetti F, Fugazza A, Castelli F, Colombo M, Lampertico P.

J Clin Virol. 2014 Dec;61(4):600-3. doi: 10.1016/j.jcv.2014.09.016. Epub 2014 Oct 5.

PMID:
25453573
13.

Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil.

Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH.

Hepatology. 2009 Sep;50(3):727-34. doi: 10.1002/hep.23044.

PMID:
19517525
14.

Telbivudine improves renal function in patients with chronic hepatitis B.

Gane EJ, Deray G, Liaw YF, Lim SG, Lai CL, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M, Samuel D, Uddin A, Bosset S, Trylesinski A.

Gastroenterology. 2014 Jan;146(1):138-146.e5. doi: 10.1053/j.gastro.2013.09.031. Epub 2013 Sep 22.

PMID:
24067879
15.

Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B.

Jia HY, Ding F, Chen JY, Lian JS, Zhang YM, Zeng LY, Xiang DR, Yu L, Hu JH, Yu GD, Cai H, Lu YF, Zheng L, Li LJ, Yang YD.

World J Gastroenterol. 2015 Mar 28;21(12):3657-62. doi: 10.3748/wjg.v21.i12.3657.

16.

[Changes in serum β2-microglobulin, retinol-binding protein, and cystatin C and their value in identifying early renal dysfunction in patients with chronic hepatitis B undergoing tenofovir or entecavir monotherapy: a comparative analysis].

He J, Ning HB, Zeng YL, Li W, Li K, Shang J.

Zhonghua Gan Zang Bing Za Zhi. 2016 Sep 20;24(9):643-646. doi: 10.3760/cma.j.issn.1007-3418.2016.09.002. Chinese.

PMID:
27788718
17.

Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection.

Mallet V, Schwarzinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, Pol S.

Clin Gastroenterol Hepatol. 2015 Jun;13(6):1181-8.e1. doi: 10.1016/j.cgh.2014.11.021. Epub 2014 Nov 21.

PMID:
25460550
18.

Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.

Pradat P, Le Pogam MA, Okon JB, Trolliet P, Miailhes P, Brochier C, Maynard M, Bailly F, Zoulim F, Cotte L.

J Viral Hepat. 2013 Sep;20(9):650-7. doi: 10.1111/jvh.12088. Epub 2013 Mar 5.

PMID:
23910650
19.

Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.

Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, Hoofnagle JH.

Aliment Pharmacol Ther. 2012 Jun;35(11):1317-25. doi: 10.1111/j.1365-2036.2012.05093.x. Epub 2012 Apr 16.

20.

Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S.

PLoS One. 2011;6(7):e22661. doi: 10.1371/journal.pone.0022661. Epub 2011 Jul 25.

Supplemental Content

Support Center